Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 14;9(7):003451.
doi: 10.12890/2022_003451. eCollection 2022.

When Autoimmunity 'DRESSes up': A Case after Certolizumab Therapy

Benedetta Marigliano  1 , Federico Rosa  2 , Mattia Internullo  1 , Luigi Scuro  1 , Andrea Tavanti  1 , Lucia Rita Del Vecchio  1 , Francesco Paolo Romagno  1 , Maria Barbara Schito  1 , Federica Pace  1 , Giovanni Maria Colombo  1 , Emanuele Guglielmelli  1
Affiliations

When Autoimmunity 'DRESSes up': A Case after Certolizumab Therapy

Benedetta Marigliano et al. Eur J Case Rep Intern Med. .

Abstract

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterised by skin rash together with visceral organ involvement, lymphadenopathy, eosinophilia and atypical lymphocytosis. The syndrome is clinically heterogeneous, making diagnosis challenging. It has an annual incidence of 2 per 100,000 population and a mortality rate of 2-10%. We describe the first case of DRESS induced by certolizumab, a biologic disease-modifying antirheumatic drug (bioDMARD).

Learning points: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is an uncommon and under-reported syndrome.Its recognition is critical for treatment, especially in the emergency setting where most patients first present.In the case of unexplained fever, lymphadenopathy, cutaneous rash and characteristic laboratory findings (e.g., eosinophilia), after infectious causes have been ruled out, clinicians should always keep DRESS in mind and consider possible recent intake of a triggering drug.

Keywords: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); certolizumab; eosinophilia; lymphadenopathy; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interest

References

    1. Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, Blumenthal KG. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome identified in the electronic health record allergy module. J Allergy Clin Immunol Pract. 2019;7:633–640. - PMC - PubMed
    1. Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22:1044–1049. - PubMed
    1. Bocquet H, Bagot M, Roujeau JC. Drug induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS) Semin Cutan Med Surg. 1996;15:250–257. - PubMed
    1. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–1080. - PubMed
    1. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;22:489–501. - PubMed

LinkOut - more resources